^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Glioblastoma |
| Drug: | olaptesed pegol (NOX-A12) (CXCL12 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
TME Pharma Receives US FDA Fast Track Designation for Lead Asset NOX-A12 in Brain Cancer
Published date:
04/02/2024
Excerpt:
...FDA) has granted Fast Track designation for NOX-A12 (olaptesed pegol), TME Pharma's CXCL12 inhibitor, in combination with radiotherapy and bevacizumab for use in the treatment of the aggressive adult brain cancer, glioblastoma, in the newly diagnosed setting where the tumor is resistant to chemotherapy and measurable tumor remains after surgery.
